Medicus Pharma Reports 80% ORR in SkinJect Phase 2 Study, Eyes AI-Driven Drug Development
Event summary
- Medicus Pharma reported an 80% overall response rate (ORR) in the 200µg cohort of its Phase 2 SkinJect study, with 73% clinical clearance at Day 57.
- The company plans to discuss regulatory engagement and strategic partnerships during an upcoming business update call on March 26, 2026.
- Medicus raised $31.9 million in 2025 and had $8.7 million in cash reserves as of year-end 2025.
- The company is developing an agentic AI-enabled clinical development platform to optimize trial design and patient stratification.
The big picture
Medicus Pharma's strong Phase 2 results for SkinJect position it as a potential non-surgical alternative for basal cell carcinoma, a market with significant unmet needs. The company's focus on AI-driven drug development aligns with broader industry trends toward data-driven clinical trials and capital efficiency. With a catalyst-rich 2026 ahead, including regulatory meetings and strategic partnerships, Medicus is poised to accelerate its growth in the biotech sector.
What we're watching
- Regulatory Pathway
- Whether the FDA will align on a registrational pathway for SkinJect following the End-of-Phase 2 meeting.
- AI Integration
- The pace at which Medicus can implement its AI-driven clinical development platform to improve trial efficiency.
- Strategic Partnerships
- How potential partnerships with Helix Nanotechnologies and Reliant AI will impact Medicus' drug development pipeline.
Related topics